TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend

Bulletin Express

05/27

TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.

As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.

The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1103043142"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103043142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103043142?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103043142","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.</p>\n<p>As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.</p>\n<p>The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics sets 8 June 2026 board meeting to weigh potential final dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-27 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.</p>\n<p>As disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.</p>\n<p>The notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1103043142","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103043142","pubTimestamp":1779877383,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics定于2026年6月8日召开董事会会议，权衡潜在的末期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited has notified shareholders that its board of directors will convene on 8 June 2026. The primary agenda item is to deliberate on the recommendation of a final dividend, if any, for the most recent financial year.\nAs disclosed, the current board consists of one executive director—Chairman and CEO Dr. Ma Zhenkun—two non-executive directors, Dr. Song Gaoguang and Mr. Michael James Bakes, and three independent non-executive directors, Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping.\nThe notice, released in Hong Kong on 27 May 2026, indicates that further details, including any dividend proposal, will follow the board’s deliberations. Investors and stakeholders are advised to monitor subsequent announcements for the board’s final resolution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}